Notice of Board Meeting

Phase 3 Clinical Trial Completed in China for Boan Biotech’s Dulaglutide Injection BA5101. BLA to be filed soon

Yantai, March 8, 2024 – Boan Biotech (6955.HK) today announced the completion of a Phase 3 clinical trial (a comparative study of efficacy, safety, and immunogenicity) for its Dulaglutide Inject...

Voluntary Announcement Phase 3 Clinical Trial Completed in China for Dulaglutide Injection (BA5101) and BLA to be Filed

Monthly Return of Equity Issuer on Movements in Securities for the month ended 29 February 2024

Arrangement of Electronic Dissemination of Corporate Communications[Registered H shareholders]

Arrangement of Electronic Dissemination of Corporate Communications[Non-registered H shareholds]

Notification Letter to Non-registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Notification Letter to Registered H Shareholders and Reply Form - Arrangement of Electronic Dissemination of Corporate Communications

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2024

Boan Biotech Authorizes Zencore Biologics to Use Its BA-HIEXcell® Stable Cell Line Development Platform

The platform can enhance the efficiency of biologics development by creating stable and highly expressed cell linesYantai, China, January 30, 2024 -- Boan Biotech (6955.HK) has entered into an agreeme...